Amphiregulin Polyklonaler Antikörper

• Featured Product
• KD/KO Validated

Amphiregulin Polyklonal Antikörper für IF

Wirt / Isotyp

Kaninchen / IgG

Getestete Reaktivität

human

Anwendung

IF

Konjugation

CoraLite® Plus 488 Fluorescent Dye

Kat-Nr. : CL488-16036

Synonyme

amphiregulin, AR, AREG, AREGB, CRDGF, SDGF

---

Galerie der Validierungsdaten

• 

  IF Staining of human colon cancer using CL488-16036

  Immunofluorescent analysis of (4% PFA) fixed human colon cancer tissue using CoraLite® Plus 488 Amphiregulin antibody (CL488-16036) at dilution of 1:200.

---

Geprüfte Anwendungen

• Erfolgreiche Detektion in IF: humanes Kolonkarzinomgewebe

Empfohlene Verdünnung

• Immunfluoreszenz (IF): IF : 1:50-1:500

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Produktinformation

CL488-16036 bindet in IF Amphiregulin und zeigt Reaktivität mit human

• Getestete Reaktivität: human
• Wirt / Isotyp: Kaninchen / IgG
• Klonalität: Polyklonal
• Typ: Antikörper
• Immunogen: Amphiregulin fusion protein Ag8907
• Vollständiger Name: amphiregulin
• Berechnetes Molekulargewicht: 252 aa, 28 kDa
• GenBank-Zugangsnummer: BC009799
• Gene symbol: AREG
• Gene ID (NCBI): 374
• Konjugation: CoraLite® Plus 488 Fluorescent Dye
• Excitation/Emission maxima wavelengths: 493 nm / 522 nm
• Form: Liquid
• Reinigungsmethode: Antigen-Affinitätsreinigung
• Lagerungspuffer: BS mit 50% Glyzerin, 0,05% Proclin300, 0,5% BSA, pH 7,3.
• Lagerungsbedingungen: Bei -20°C lagern. Vor Licht schützen. Aliquotieren ist bei -20^oC Lagerung nicht notwendig. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

Amphiregulin (AREG) is one of the ligands of the epidermal growth factor receptor (EGFR). AREG plays a central role in mammary gland development and branching morphogenesis in organs and is expressed both in physiological and in cancerous tissues. The AREG protein is synthesized as a 252-amino acid transmembrane precursor, pro-AREG. At the plasma membrane, pro-AREG is subjected to sequential proteolytic cleavages within its ectodomain and is then released as the soluble AREG protein. Depending on the cell type and microenvironment, AREG can be produced in multiple cellular and mature forms using alternative pro-AREG cleavage sites and glycosylation motifs. Post-translastional modfications of 50-kDa pro-AREG produces a major soluble 43-kDa form, 28-, 26-, 16-kDa membrane anchored forms, and soluble 21-, 19-, and 9-kDa forms (PMID: 9642297).